<DOC>
	<DOCNO>NCT00107861</DOCNO>
	<brief_summary>This study conduct subject refractory colorectal carcinoma unresectable liver metastasis . The purpose study : - evaluate safety harmful effect intravenous injection Ad.hIFN-β ; - help determine whether virus carry interferon-beta gene enter bloodstream liver tumor cell cause cancer cell die .</brief_summary>
	<brief_title>Interferon-Beta Gene Transfer ( Ad.hIFN-β ) Treatment Refractory Colorectal Carcinoma With Liver Metastases</brief_title>
	<detailed_description>This trial clinical research study Ad.hIFN-β , investigational , replication-defective , recombinant adenovirus contain human interferon beta gene , people refractory colorectal carcinoma liver metastasis . Scientists explore variety approach develop medication treat patient refractory colorectal carcinoma liver metastases ; disease current treatment provide limited relief , need new medication .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Subjects histologically confirm hepatic metastasis primary colorectal carcinoma . Not amenable complete surgical resection attempt cure determine Principal Investigator ( PI ) . Tumor progression prior therapy colorectal carcinoma , include fluoropyrimidine ( 5 FU capecitabine ) , irinotecan , oxaliplatin , cetuximab . One metastatic hepatic tumor measurable CT scan . In addition , subject may nonhepatic metastatic tumor . ECOG performance status ≤ 1 . Age ≥ 18 year . Signed , write IRBapproved informed consent . Men woman reproductive potential must willing follow accept birth control method treatment 3 month completion treatment . Acceptable liver function : Bilirubin ≤ 1.5 x upper limit normal ; AST , ALT ≤ 2.0 x upper limit normal ; Albumin ≤ 3.0 g/dL . Acceptable hematologic status : Granulocyte ≥ 1000 cells/mm3 ; Platelet count ≥ 150,000 plts/mm3 ; Hemoglobin &gt; 9 g/dL . Acceptable coagulation status : INR within normal limit . Acceptable kidney function : Serum creatinine within normal limit . New York Heart Association Class III IV cardiac disease , myocardial infarction within past 6 month prior Day 1 , unstable arrhythmia , evidence ischemia ECG within 14 day prior Day 1 . Seizure disorder require anticonvulsant therapy . Severe chronic obstructive pulmonary disease hypoxemia . Major surgery , diagnostic surgery , within 4 week prior Day 1 . Active uncontrolled bacterial , viral , fungal infection , require systemic therapy . Pregnant nursing woman . Treatment radiation therapy , surgery , chemotherapy , investigational therapy within 1 month prior study entry . Unwillingness inability comply procedure require protocol . Known infection HIV , hepatitis B , hepatitis C. Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , condition ) could compromise protocol objective opinion investigator and/or sponsor . Clinically significant bleeding event within last 3 month , unrelated trauma . More 50 % liver replace tumor ( estimate PI CT scan within 14 day Day 1 ) . Previous treatment Ad.hIFNβ . Any prior treatment gene delivery vector adenovirus therapeutic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>